Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.

Jammbe Z MusoroCorneel CoensFrederic FiteniPogoda KatarzynaFatima CardosoNicola S RussellMadeleine T KingKim CocksMirjam Ag SprangersMogens GroenvoldGalina VelikovaHans-Henning FlechtnerAndrew Bottomleynull null

Published in: JNCI cancer spectrum (2019)

Our findings aid interpretation of changes in EORTC QLQ-C30 scores over time, both within and between groups, and for performing more accurate sample size calculations for clinical trials in advanced breast cancer.

Keyphrases

clinical trial
molecular dynamics
density functional theory
molecular dynamics simulations
high resolution
randomized controlled trial
mass spectrometry
breast cancer risk